Teresa Parsons
Overview
Explore the profile of Teresa Parsons including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
379
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Weld E, McGowan I, Anton P, Fuchs E, Ho K, Carballo-Dieguez A, et al.
J Infect Dis
. 2023 Nov;
229(4):1131-1140.
PMID: 38019657
Background: Despite highly effective HIV preexposure prophylaxis (PrEP) options, no options provide on-demand, nonsystemic, behaviorally congruent PrEP that many desire. A tenofovir-medicated rectal douche before receptive anal intercourse may provide...
2.
Ferguson S, Al Rifai F, Maaya M, Nguyen L, Qureshi K, Tse A, et al.
Int Nurs Rev
. 2016 Mar;
63(1):15-25.
PMID: 26923323
Aim: The aim of this article was to present experiences from the field in the context of the International Council of Nurses' Leadership for Change™ programme, which celebrates 20 years...
3.
Kelen G, Hsieh Y, Rothman R, Patel E, Laeyendecker O, Marzinke M, et al.
AIDS
. 2016 Jan;
30(1):113-20.
PMID: 26731757
Objective: The Johns Hopkins Hospital Emergency Department has served as a window on the HIV epidemic for 25 years, and as a pioneer in emergency department-based screening/linkage-to-care (LTC) programs. We...
4.
Wright P, Alex A, Harvey S, Parsons T, Pullen F
Analyst
. 2013 Sep;
138(22):6869-80.
PMID: 24071718
Fragmentation of molecules under collision-induced dissociation (CID) conditions is not well-understood. This may make interpretation of MSMS spectra difficult and limit the effectiveness of software tools intended to aid mass...
5.
Mirochnick M, Taha T, Kreitchmann R, Nielsen-Saines K, Kumwenda N, Joao E, et al.
J Acquir Immune Defic Syndr
. 2013 Aug;
65(1):33-41.
PMID: 23979002
Background: Data describing the pharmacokinetics and safety of tenofovir in neonates are lacking. Methods: The HIV Prevention Trials Network 057 protocol was a phase 1, open-label study of the pharmacokinetics...
6.
Beigi R, Noguchi L, Parsons T, Macio I, Kunjara Na Ayudhya R, Chen J, et al.
J Infect Dis
. 2011 Sep;
204(10):1527-31.
PMID: 21930612
Unlabelled: Tenofovir (TFV) 1% vaginal gel has been found to decrease sexual transmission of human immunodeficiency virus. To initiate investigations during pregnancy, 16 healthy pregnant women scheduled for cesarean delivery...
7.
Crawford K, Spritzler J, Kalayjian R, Parsons T, Landay A, Pollard R, et al.
AIDS Res Hum Retroviruses
. 2010 Jun;
26(6):635-43.
PMID: 20560793
The advent of highly active antiretroviral therapy in the treatment of HIV disease has substantially extended the lifespan of individuals infected with HIV resulting in a growing population of older...
8.
Wright P, Alex A, Nyaruwata T, Parsons T, Pullen F
Rapid Commun Mass Spectrom
. 2010 Mar;
24(7):1025-31.
PMID: 20213631
Tandem mass spectrometry (MS/MS) is widely used for the identification of metabolites at all stages of the pharmaceutical discovery and development process. The assignment of ions in the product ion...
9.
Flexner C, Tierney C, Gross R, Andrade A, Lalama C, Eshleman S, et al.
Clin Infect Dis
. 2010 Mar;
50(7):1041-52.
PMID: 20192725
Background: Dosing frequency is an important determinant of regimen effectiveness. Methods. To compare efficacy of once-daily (QD) versus twice-daily (BID) antiretroviral therapy, we randomized human immunodeficiency virus (HIV)-positive, treatment-naive patients...
10.